Evidence map›Paper›PMID 40810148›Full record

ArticleACS pharmacology & translational science2025

Technetium-99m-Labeled Fibroblast Activation Protein-Targeted Nanobody Radiotracer: from Preclinical Development to Clinical Translation in Cancer Imaging.

Chenzhen Li, Xinru Li, Yuchen Wang, Zhidong Bai, Yuanbo Wang, Rui Gao, Bing Jia

Abstract read
In one paragraph

Article in ACS pharmacology & translational science, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Chenzhen LiDepartment of Radiation Medicine, School of Basic Medical Sciences, Peking University, Beijing 100191, China.
Xinru LiDepartment of Nuclear Medicine, The First Affiliated Hospital of Xi'an Jiaotong University, 277W Yanta Road, Xi'an 710061, China.
Yuchen WangDepartment of Radiation Medicine, School of Basic Medical Sciences, Peking University, Beijing 100191, China.
Zhidong BaiDepartment of Radiation Medicine, School of Basic Medical Sciences, Peking University, Beijing 100191, China.
Yuanbo WangDepartment of Nuclear Medicine, The First Affiliated Hospital of Xi'an Jiaotong University, 277W Yanta Road, Xi'an 710061, China.
Rui GaoDepartment of Nuclear Medicine, The First Affiliated Hospital of Xi'an Jiaotong University, 277W Yanta Road, Xi'an 710061, China.
Bing JiaDepartment of Radiation Medicine, School of Basic Medical Sciences, Peking University, Beijing 100191, China.ORCID https://orcid.org/0000-0001-9346-1217

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Fibroblast activation protein (FAP) is a highly expressed marker in cancer-associated fibroblasts (CAFs) across various epithelial cancers, making it an attractive target for diagnostic imaging. To address the limitations of existing FAP-targeted radiopharmaceuticals, such as poor tumor retention and off-target uptake, this study aimed to establish a comprehensive FAP nanobody library. Through systematic screening, we sought to identify a nanobody with cross-reactivity to both human and murine FAP, optimized for technetium-99m (

Indexed as

fibroblast activation proteinnanobodypreliminary clinical trialsSPECT imaging

Identifiers

PMID40810148
PMCPMC12340623

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.